228 related articles for article (PubMed ID: 25114021)
1. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.
Tandstad T; Ståhl O; Håkansson U; Dahl O; Haugnes HS; Klepp OH; Langberg CW; Laurell A; Oldenburg J; Solberg A; Söderström K; Cavallin-Ståhl E; Stierner U; Wahlquist R; Wall N; Cohn-Cedermark G;
Ann Oncol; 2014 Nov; 25(11):2167-2172. PubMed ID: 25114021
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
3. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.
Cohn-Cedermark G; Stahl O; Tandstad T;
Andrology; 2015 Jan; 3(1):102-10. PubMed ID: 25270123
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
Fischer S; Tandstad T; Cohn-Cedermark G; Thibault C; Vincenzi B; Klingbiel D; Albany C; Necchi A; Terbuch A; Lorch A; Aparicio J; Heidenreich A; Hentrich M; Wheater M; Langberg CW; Ståhl O; Fankhauser CD; Hamid AA; Koutsoukos K; Shamash J; White J; Bokemeyer C; Beyer J; Gillessen S;
J Clin Oncol; 2020 Apr; 38(12):1322-1331. PubMed ID: 31877087
[TBL] [Abstract][Full Text] [Related]
6. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
9. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen M; Huddart R; Joffe J; Gardiner D; Maynard L; Hutton P; Mazhar D; Shamash J; Wheater M; White J; Goubar A; Porta N; Witts S; Lewis R; Hall E;
Eur Urol; 2020 Mar; 77(3):344-351. PubMed ID: 31901440
[TBL] [Abstract][Full Text] [Related]
10. [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].
Hartmann M; Siener R; Krege S; Schmelz H; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Albers P;
Urologe A; 2009 May; 48(5):523-8. PubMed ID: 19183929
[TBL] [Abstract][Full Text] [Related]
11. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy.
Oliver RT; Ong J; Shamash J; Ravi R; Nagund V; Harper P; Ostrowski MJ; Sizer B; Levay J; Robinson A; Neal DE; Williams M;
Urology; 2004 Mar; 63(3):556-61. PubMed ID: 15028457
[TBL] [Abstract][Full Text] [Related]
14. Delivery of chemotherapy for testicular cancer in routine practice: A population-based study.
Karim S; Wei X; Leveridge MJ; Siemens DR; Robinson AG; Bedard PL; Booth CM
Urol Oncol; 2019 Mar; 37(3):183.e17-183.e24. PubMed ID: 30478011
[TBL] [Abstract][Full Text] [Related]
15. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Ståhl O; Cavallin-Ståhl EK; Klepp OH; Dahl O; Cohn-Cedermark G
J Clin Oncol; 2011 Feb; 29(6):719-25. PubMed ID: 21205748
[TBL] [Abstract][Full Text] [Related]
16. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
17. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
19. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
20. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
